Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025




Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com

Hapbee Appoints New Leaders to Accelerate Women’s Wellness Through Frequency Healing Technology




Hapbee Appoints New Leaders to Accelerate Women’s Wellness Through Frequency Healing Technology

Expanding focus into FemTech positions Hapbee to scale across a USD 177 billion market by uniting neuroscience, sleep optimization, and women-led innovation

VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Hapbee Technologies Inc. (“Hapbee” or the “Company”) (TSXV: HAPB | OTCQB: HAPBF | FWB: HA1) — Hapbee Technologies Inc. (“Hapbee”), the pioneer in frequency-based digital wellness technology, today announced the appointment of Jodie Jackson as Chief Neural Optimization Officer and Nancy H. Rothstein as Chief Sleep Officer.

These additions mark a defining moment for Hapbee’s evolution as the company deepens its commitment to women’s wellness – a sector rapidly transforming the global health landscape. The initiative aligns with Hapbee’s long-term growth strategy to scale its proprietary frequency-based platform across the expanding FemTech market, which is projected to surpass USD 177 billion by 2033 with annual growth exceeding 13% CAGR (Straits Research, 2025).

Jodie Jackson, an authority in behavioral neuroscience and neuroplasticity, will lead Hapbee’s efforts to design personalized neural frequency protocols that address cognitive, emotional, and hormonal balance. Nancy H. Rothstein, MBA – internationally known as The Sleep Ambassador® – will oversee the development of Hapbee’s sleep programs and hospitality integrations, drawing on decades of experience in providing sleep information and education to optimize its impact on productivity, health, and life.

“No one is better equipped to inform the world – and shape the products that serve women – than women themselves,” said Riz Shah, Chairman of Hapbee Technologies. “As a father, son, sibling, and husband, I’ve seen firsthand how women shoulder immense emotional and physical demands. Supporting women’s wellness isn’t a marketing campaign; it’s essential to Hapbee’s mission and a major part of the next chapter of our growth. We’re incredibly proud to lead with empathy, science, and purpose.”

The company’s upcoming innovations will include new frequency routines designed to support hormonal harmony, stress management, and restorative sleep. Partnerships with women’s health networks, wellness practitioners, and hotel groups will further scale the reach of Hapbee’s technology globally.

“Everyone deserves technologies created with them in mind—not retrofitted after the fact, particularly for women,” said Nancy H. Rothstein, Chief Sleep Officer. “Sleep is critical to our health – and Hapbee offers a safe, natural path to restore rest, recharge energy, and reclaim emotional balance without consuming unnecessary pills or medicines.”

“It’s a privilege to join Hapbee in advancing women’s wellness through innovative frequency technologies,” added Jodie Jackson, Chief Neural Optimization Officer. “As a mother and working professional focused on unlocking human potential, I am excited to contribute to shaping how Hapbee’s technology can empower people to optimize focus, rest and resilience.”

About Hapbee

Hapbee Technologies Inc. is a leading wearable neuro-wellness company using proprietary ultra-low frequency technology to help people enhance their sleep, focus, and relaxation—safely and naturally. Hapbee’s products are trusted by wellness professionals, high performers, and consumers across more than 40 countries.

Forward‑Looking Information

This news release contains “forward‑looking information” within the meaning of applicable securities laws, including statements regarding Hapbee’s anticipated expansion in FemTech, and growth opportunities in wellness markets. Forward‑looking information is subject to risks and uncertainties that may cause actual results to differ materially. Hapbee undertakes no obligation to update forward‑looking information except as required by law.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the receipt of applicable regulatory approvals, closing of the offering; anticipated product development, consumer confidence and general business, economic, competitive, political and social uncertainties. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

On behalf of the Board of Directors:

Kenny Adessky – Corporate Secretary

1 888 841 7086

invest@hapbee.com

www.hapbee.com

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial




Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

• Orchestra BioMed’s Virtue® Sirolimus AngioInfusion^TM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“SirolimusEFR^TM”)
• The Virtue Trial is the first U.S. investigational device exemption (“IDE”) head-to-head randomized coronary pivotal trial evaluating a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™)
• Coronary in-stent restenosis (“ISR”), the clinical focus of the Virtue Trial, is a difficult-to-treat and serious complication of coronary stenting that increases the risk of life-threatening heart problems, affecting an estimated 100,000 patients in the U.S. annually
• Virtue SAB has FDA Breakthrough Device Designation for the treatment of coronary ISR, as well as for coronary small vessel disease and below-the-knee peripheral artery disease

NEW HOPE, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the first patient enrollments in the Virtue SAB in the Treatment of Coronary ISR Trial (“Virtue Trial”), the Company’s U.S. IDE pivotal trial comparing its highly differentiated Virtue® Sirolimus AngioInfusion^TM Balloon (“Virtue SAB”) to the AGENT paclitaxel-coated balloon, currently the only drug-coated balloon (“DCB”) FDA-approved for a coronary indication. The initial cases were successfully completed by the teams at The Christ Hospital Heart & Vascular Institute in Cincinnati, OH, and St. Francis Hospital & Heart Center in Roslyn, NY, marking the initiation of the Virtue Trial. Dean J. Kereiakes, M.D., FACC, MSCAI, Chairman of The Christ Hospital Heart & Vascular Institute and Medical Director of The Christ Hospital Research Institute and Allen Jeremias M.D., Director of Interventional Cardiology Research and Associate Director, Cardiac Catheterization Laboratory, St. Francis Hospital & Heart Center are co-principial investigators of the Virtue Trial. Designed to support regulatory approval of Virtue SAB, the Virtue Trial is expected to enroll 740 patients at up to 75 centers in the United States with enrollment completion currently planned for mid-2027.

Virtue SAB: Redefining Delivery of Sirolimus
“Virtue SAB and SirolimusEFR were specifically designed to optimize the dose, delivery, uptake and extended release of sirolimus without the limitations of a drug coating on the balloon surface. A substantial body of clinical evidence from drug-eluting stent studies has established sirolimus and its analogs as the gold-standard drug for promoting vessel healing and preventing restenosis following interventional procedures,” said Jarrod D. Frizzell, MD, MS, FACC, FSCAI, Director of Complex Coronary Therapeutics, Interventional Cardiology, The Christ Hospital Health Network. “The Virtue Trial will allow us to evaluate the performance of this fundamentally different approach to delivering sirolimus, which has shown promising results in a prior pilot clinical study in coronary ISR treatment, in direct comparison to the AGENT paclitaxel-coated balloon.”

Additionally, Dr. Jeremias commented, “Drug coated balloons offer a promising alternative to drug-eluting stents for the treatment of coronary indications such as coronary ISR. Virtue SAB and SirolimusEFR are designed to go beyond DCBs with the goal of optimizing drug dosing, tissue uptake and extended drug bioavailability at the site of treatment. Our team at St. Francis is excited to play a leadership role in the Virtue Trial which will evaluate this differentiated, non-coated drug-delivery system head-to-head versus the current market leading DCB.”

Virtue SAB is designed to deliver a large liquid dose of a proprietary extended-release formulation of sirolimus, SirolimusEFR™, through a non-coated microporous AngioInfusion™ Balloon that protects the drug in transit and helps overcome certain limitations of DCBs. SirolimusEFR™ is designed to enable enhanced tissue uptake and extended release of therapeutic levels of sirolimus through the critical healing period, exceeding previously published target tissue concentrations of proven drug-eluting stents.​ In the multi-center SABRE pilot study, Virtue SAB demonstrated promising clinical results for the treatment of single-layer coronary ISR:

• 12-month target lesion failure of 2.8%
• Zero target lesion revascularizations from 12-month follow-up through 36-month follow-up; and
• 6-month late lumen loss of 0.12mm.

Virtue SAB has FDA Breakthrough Device Designation for the treatment of coronary ISR, as well as for coronary small vessel disease and below-the-knee peripheral artery disease. Orchestra BioMed estimates the total global market opportunity for drug-eluting balloons to be over $10 billion annually.

A Head-to-Head Randomized Evaluation of a Sirolimus-Eluting Balloon vs. a Paclitaxel-Coated Balloon
The Virtue Trial is a prospective, multi-center, randomized trial comparing clinical outcomes of Virtue SAB to AGENT Paclitaxel DCB in the treatment of coronary ISR. Data from the Virtue Trial is expected to be used to support regulatory approval in the U.S. The primary endpoint is a non-inferiority comparison of Target Lesion Failure (TLF) defined as a composite of cardiac death, nonfatal target vessel myocardial infarction and ischemia-driven target lesion revascularization at 12 months. The trial is expected to randomize 740 patients across up to 75 centers in the U.S.

Darren R. Sherman, President and Chief Operating Officer of Orchestra BioMed stated, “We believe the future of arterial disease treatment will be driven by optimized delivery and extended tissue release of therapeutic doses of sirolimus, the proven antiproliferative drug with well-established safety and effectiveness. Balloon surface-coating drug delivery has challenges and limitations, including dosing constraints, drug-loss that requires rapid device navigation, and the release of large embolic particulates. We designed Virtue SAB and its key enabling technology, our proprietary SirolimusEFR, to overcome these limitations and realize the full potential of arterial drug delivery during angioplasty. With the launch of the Virtue Trial, we’re taking a major step toward realizing our vision of improving patient outcomes.”

About Coronary In-Stent Restenosis (ISR)
Coronary ISR is a serious complication of coronary stenting, which can increase the risk of life-threatening heart problems. It is characterized by re-narrowing of a coronary artery segment that was previously treated with a stent. According to the National Cardiovascular Data Registry, coronary ISR occurs in up to 10% of stented patients during the first year and continues at a rate of up to 3% per year thereafter, resulting in an estimated over 325,000 coronary ISR lesions annually worldwide that may require treatment. If left untreated, coronary ISR may lead to stable angina, unstable angina, acute coronary syndrome, acute myocardial infarction, or death.

About Virtue SAB
Virtue SAB is a highly differentiated, first-of-its-kind drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™. It uses a patented non-coated microporous AngioInfusion™ Balloon to protect the drug in transit and consistently deliver a large liquid dose, overcoming certain limitations of drug-coated balloons. SirolimusEFR delivered by Virtue SAB has been shown in published preclinical series involving hundreds of arterial deliveries to achieve therapeutic levels of extended-release sirolimus through the critical healing period, exceeding published target tissue concentration of proven drug-eluting stents. Virtue SAB and SirolimusEFR demonstrated positive three-year clinical data in coronary ISR in the SABRE study, a multi-center, prospective, independent core lab-adjudicated clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion^TM Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the enrollment, timing, implementation and design of the Virtue Trial, the ability of data from the Virtue Trial to support regulatory approval in the U.S., the potential efficacy and safety of the Company’s commercial product candidates, the ability of the Company’s partnerships to accelerate clinical development, and the Company’s late-stage development programs, strategic partnerships and plans to expand its product pipeline. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; failure to realize the anticipated benefits of the business combination; risks related to regulatory approval of the Company’s product candidates; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and the risk factor discussed under the heading “Item 1A. Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which was filed with the SEC on May 12, 2025, as updated by any risk factors disclosed under the heading “Item 1A. Risk Factors” in the Company’s subsequently filed quarterly reports on Form 10-Q.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
Kkirkellis@orchestrabiomed.com

Curia Invests $4 Million to Enhance Sterile API Manufacturing




Curia Invests $4 Million to Enhance Sterile API Manufacturing

ALBANY, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its two API aseptic suites in Valladolid, Spain. The investment aligns with the latest EU GMP Annex 1 standards and reinforces Curia’s longstanding commitment to regulatory excellence and product quality. Annex 1 provides general guidance for the design and control of facilities, equipment, systems and procedures used for the manufacture of all sterile products, applying the principles of Quality Risk Management (QRM) to prevent microbial, particulate and endotoxin contamination in the final product.

The enhancements support upgrades to Valladolid’s infrastructure and technology. Curia used innovative tools to take advantage of new possibilities derived from the application of an enhanced process understanding. The bulk of the investment was dedicated to updating the site’s equipment, including the installation of new isolators, along with modernizations to HVAC, pharmaceutical panels, automation, sterilization in place and general utilities. Transitioning to a fully closed system was the primary driver of these upgrades, with the goal of supporting process and product safety and preventing microbiological contamination at every step of production. Additionally, ergonomic improvements for operators were key to increasing operational safety, along with the implementation of additional automatic controls in line with stricter data integrity policies, as described in 21 CFR Part 11.    

“Quality and compliance are integral to how we operate,” said Philip Macnabb, CEO of Curia. “The new Annex 1 requirements align with our proactive approach to quality control. We always strive to offer our customers the highest level of assurance when it comes to compliance and our ability to deliver high-quality sterile APIs at scale. Customers depend on us for reliability, precision and trust. With these improvements at Valladolid, they can feel confident that we will continue to invest ahead of industry trends as we partner with them to bring their products to market.”

The updates at Valladolid followed a company-wide evaluation across Curia’s global network to identify opportunities for improvement related to new Annex 1 requirements. The assessment examined procedures, equipment, utilities, qualifications, and validations to create solutions tailored to each site and to address any areas for optimization.

Curia’s global API aseptic processing manufacturing network has served a broad portfolio of customers worldwide for more than 20 years. This investment positions the company to support increasingly complex manufacturing projects, while strengthening its commitment to delivering life-changing medicines with uncompromising quality and reliability.

About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20 global sites and 3,200 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs, sterile drug product and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory-compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion – Strengthening Balance Sheet and Supporting Growth




Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion – Strengthening Balance Sheet and Supporting Growth

DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the Company welcomes the indicated intention of its largest investor and primary lender, Perceptive Advisors, to submit a proposal that, if implemented, would facilitate the conversion of a portion of the Company’s outstanding debt and other obligations into equity.

The Company believes this strategic initiative represents a constructive step toward strengthening its balance sheet and that an equitization program, if successfully executed, could enhance the Company’s financial flexibility and support its ambitious growth objectives.

Perceptive Advisors is a leading life sciences investment firm that has continued to be a supportive and constructive investment partner to the Company through its recent transformation journey.

The Company looks forward to engaging in discussions that are mutually beneficial and aligned with the interests of all of its stakeholders, including shareholders.

Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, the impact of the U.S. government shut-down, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company’s website: www.trinitybiotech.com.

About Perceptive Advisors

Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment management firm with approximately $8 billion in assets. Perceptive Advisors is focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. For more information visit www.perceptivelife.com.

Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer




Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer

Healthcare veteran brings expertise in clinical care delivery, digital health, and policy to virtual-first healthcare provider

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) — Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology. In this role, he will lead Omada’s clinical organization while advancing clinical quality, outcomes, strategy, and innovation across Omada’s multi-condition platform.

“Dr. Tsang’s exceptional track record in building a virtual care delivery platform makes him the ideal clinical leader to help drive Omada’s next phase of growth,” said Sean Duffy, CEO and Co-Founder of Omada Health. “As founding CEO and later Chief Strategy Officer of Valera Health, he successfully scaled virtual specialty care while maintaining clinical excellence and expanding access to underserved populations. His rare combination of hands-on clinical practice, policy expertise, and engagement in the national healthcare quality framework will be instrumental as we work to bend the curve of chronic disease.”

Dr. Tsang currently serves on the boards of Blue Cross and Blue Shield of Kansas City and the National Committee for Quality Assurance (NCQA). As founding CEO of Valera Health, he led the company through significant growth, raising over $75 million in funding and scaling to more than 500 employees in five years. Valera, which delivers high-quality behavioral health specialty care for high acuity patients, earned recognition from Digital Health New York¹ and Fast Company² for its innovative approach to care delivery.

His earlier experience includes serving as Chief Medical Officer of Merck Healthcare Services and Solutions, a Merck subsidiary focused on digital health solutions. As Medical Director at the Office of the National Coordinator for Health Information Technology under the Obama Administration, he helped shape a national framework for electronic health records to improve care coordination and quality. Dr. Tsang also contributed to the development of the Affordable Care Act while serving as a Robert Wood Johnson Foundation/Institute of Medicine Health Policy Fellow on the U.S. House Ways and Means Committee. Dr. Tsang began his career as Chief Medical Officer of the Charles B. Wang Community Health Center and served on the New York City Board of Health.

“I am thrilled to join Omada Health at this pivotal moment in healthcare delivery,” said Dr. Tsang. “As we witness the convergence of virtual care innovation and the growing prevalence of chronic conditions, Omada’s evidence-based approach and multi-condition platform are uniquely positioned to improve care delivery. Throughout my career, I’ve focused on leveraging technology to expand access to high-quality care while maintaining clinical rigor. Omada’s vision aligns with this mission, and I look forward to working with the team to advance this important work.”

Dr. Tsang’s appointment comes at a strategic time for Omada Health as the company strengthens its position in an evolving digital healthcare landscape. The company continues to expand the scale of its GLP-1 Care Track, which has served over 100,000 members since launch. Simultaneously, Omada is expanding its artificial intelligence capabilities, as demonstrated by the recent launch of OmadaSpark for nutrition education and motivational interviewing and Meal Map for personalized nutrition guidance. These focus areas reflect Omada’s commitment to combining innovative technology with human-led care to drive member engagement and improved health outcomes.

Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.

The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work^®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.

Great Place to Work^® is the registered trademark of the Great Place to Work Institute and is used under license.

Contacts
Rose Ramseth
press@omadahealth.com

Citations

1. Digital Health New York. 2025 New York Healthcare Innovation Report. Published February 6, 2025. Accessed October 8, 2025. https://static1.squarespace.com/static/62c854a63c491014a5fa45ce/t/67a50d949c7d7622cefb5d59/1738870165741/DHNY+2025+New+York+Healthcare+Innovation+Report.pdf.
2. Valera Health. Valera Health named in Fast Company’s second annual list of Brands That Matter. Published October 26, 2022. Accessed October 8, 2025. https://www.prnewswire.com/news-releases/valera-health-named-in-fast-companys-second-annual-list-of-brands-that-matter-301658596.html

Philips introduces industry-first cath lab integration that automatically synchronizes pre-operative CT with C-arm movement, paving the way for CT-guided PCI




Philips introduces industry-first cath lab integration that automatically synchronizes pre-operative CT with C-arm movement, paving the way for CT-guided PCI

October 27, 2025                                                    

New integration of Philips Advanced Visualization Workspace* with the Azurion image-guided therapy platform automatically synchronizes CT images with C-arm movement, supporting workflow efficiency and additional anatomical insights in PCI procedures¹

San Francisco, USA and Amsterdam, The Netherlands – At the annual Transcatheter Cardiovascular Therapeutics (TCT 2025) meeting, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced an industry-first innovation that integrates pre-operative CT data directly into the cath lab workflow. This new capability, available through the integration of Philips’ Advanced Visualization Workspace (AVW) with the Azurion image-guided therapy system, marks a first step towards CT-guided percutaneous coronary intervention (PCI), a minimally invasive procedure to open narrowed coronary arteries and restore blood flow to the heart.

The new capability, Follow C-arm, automatically synchronizes the 3D reconstruction of coronary arteries with the movement of the Azurion C-arm. As the C-arm angulation changes, the CT volume rotates in real time to match, giving interventionalists the 3D anatomical view without manual interaction. This seamless connection helps clinicians combine the detailed insights of CT imaging with the flexibility of live X-ray guidance inside the cath lab. The combined AVW–Azurion approach aims to provide enhanced anatomical insights to guide complex PCI procedures, publications have shown that leveraging CCTA may lead to reduction in contrast medium use and radiation dose during interventions.¹

Supporting the shift towards CT-guided PCI
Coronary computed tomography angiography (CCTA) is increasingly used in global clinical guidelines as a first-line tool for the diagnosis and planning of coronary artery disease. With more patients now arriving at the cath lab with prior CT scans, physicians are seeking ways to incorporate this information into their interventional workflows. By integrating CT data directly into Azurion, Philips is helping interventionalists expand the use of CT beyond diagnosis and planning, supporting a future in which CT-guided PCI becomes standard practice.

“By bringing pre-operative CT into the cath lab and linking it directly to the movement of the C-arm, Philips is delivering an industry-first that helps interventionalists prepare for and execute PCI procedures with greater confidence,” said Mark Stoffels, Business Leader Image-Guided Therapy Systems at Philips. “This seamless integration is a significant step towards CT-guided PCI, aligning with our commitment to improving workflow efficiency and advancing patient care in interventional cardiology.”

The launch builds on the global success of Philips’ Azurion image-guided therapy platform, the world’s leading system designed for seamless integration of advanced applications. Since its introduction in 2017, Azurion has been used to treat more than 6.4 million patients annually in over 80 countries, helping physicians perform minimally invasive procedures with greater confidence and efficiency.

For more information about Philips’ presence at TCT, please visit the Philips TCT 2025 landing page.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Disclaimer: * The Follow C-arm capability as part of Philips Advanced Visualization Workspace may not be available in all markets. Please contact your Philips representative for more details.
Reference: 1. J Cardiovasc Comput Tomogr. 2025 May-Jun;19(3):277-290.

Attachments

• Philips Follow C-arm capability
• Follow C-arm

Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis




Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis

Clinical and Pharmacology Data Presented at ACR Convergence 2025

• In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients with osteoarthritis (OA)
• A significant correlation between improvements in OA symptoms and positive effects on bone structure suggests disease modification potential
• In newly reported pre-clinical data, there was no evidence of worsening of joint pathology with LEVI-04 treatment. LEVI-04 demonstrated improvement in joint pathology with chondroprotection, and reduced bone erosion compared to controls in an established disease model of OA
• Pharmacology data presented for the first time demonstrated LEVI-04 bound all neurotrophins (NT) with highest affinity for NT-3, supporting a favourable safety profile for patients with OA

SANDWICH, United Kingdom, Oct. 27, 2025 (GLOBE NEWSWIRE) — Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is today reporting key new data from its large-scale Phase II trial of LEVI-04 in a plenary presentation at the American College of Rheumatology’s annual meeting, ACR Convergence 2025, in Chicago, Illinois.

The new clinical data, to be presented by Simon Westbrook, Founder and CSO of Levicept, are from the company’s multi-arm, multicentre, randomized, double-blind, placebo-controlled, Phase II study which enrolled 518 participants with pain and disability due to OA of the knee (ClinicalTrials.gov ID: NCT05618782). Previously presented data showed the primary efficacy endpoint of the trial was met with significant analgesia and symptom control across all doses, with a favourable safety and tolerability profile.

The new data show that LEVI-04 had positive dose-dependent effects on the size and presence of bone marrow lesions, compared to placebo. These effects correlated with improvements in pain and function, suggesting LEVI-04 may have disease modification properties in addition to the analgesic properties already reported.

The pharmacology and mechanism of action of LEVI-04 will also be presented for the first time. By supplementing endogenous soluble p75 neurotrophin binding receptor, LEVI-04 binds excess neurotrophins to regulate pain pathways while maintaining essential functions. LEVI-04 bound all neurotrophins, with highest affinity for neurotrophin-3, supporting the favourable safety profile previously presented for LEVI-04 in patients with OA.

Further presentations of Phase II data show that LEVI-04 demonstrated effect sizes for pain that met or exceeded those reported for oral NSAIDs and resulted in significantly more patients achieving the minimum clinically important difference on the StEPP (a model of evoked pain on movement), compared to placebo, and at levels historically comparable or better than NSAIDs.

In a non-clinical model of OA, LEVI-04 provided analgesia and improved joint histopathology.

Simon Westbrook, Founder and CSO of Levicept, said: “We are hugely excited by the new data we are presenting at this year’s ACR Convergence that further underline LEVI-04’s potential as a breakthrough therapy in OA.

“We present new clinical findings which suggest that LEVI-04 holds promise as a therapy to provide contemporaneous modification of joint structure – bone marrow lesions – and symptoms of OA including pain. To our knowledge, this is first time a molecule has demonstrated both disease modification and analgesia in a clinical study.

“This is supported by compelling preclinical data on LEVI-04’s mechanism of action which demonstrate it is acting in a novel way through selective inhibition of neurotrophin-3. Furthermore, preclinical studies provide additional evidence that LEVI-04 has a positive impact on disease progression.”

Eliot Forster, CEO of Levicept, said: “We believe the data we are presenting here at ACR Convergence highlight LEVI-04’s unique profile within the OA space. We have now demonstrated, in a large clinical study and backed by compelling pharmacology data, that LEVI-04 has the potential to not only significantly reduce pain but directly address the disease process. We look forward to the further clinical development of LEVI-04 and to advancing a new treatment option to millions of patients in need worldwide.”

Presentation details:

LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT

Oral plenary presentation (0852) – Monday, 27 October, 08:45 – 09:00 CST

Authors: Simon Westbrook, Ali Guermazi and Philip Conaghan

Pharmacology of LEVI-04, a novel treatment for OA

Poster presentation (1804) Tuesday, 28 October, 10:30 – 12:20 CST

Authors: Simon Westbrook and Kerry af Forselles 

LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)

Poster presentation (2101) Tuesday, 28 October, 10:30 – 12:30 CST

Authors: Philip Conaghan, Nathaniel Katz, Asger Bihlet, Laus W Wullum, Kerry af Forselles, Dr C Mike Perkins, Bernadette Hughes, Claire Herholdt, Iwona Bombelka, Simon Westbrook

Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening

Poster presentation (2081)Tuesday, 28 October, 10:30 – 12:30 CST

Authors: Ali Guermazi, Philip Conaghan, Dr C Mike Perkins, Claire Herholdt, Iwona Bombelka, Simon Westbrook

Levicept
Eliot Forster, CEO – eliot@levicept.com

Media Enquiries 
Charles Consultants 
Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585
Chris Gardner – Chris@CGComms.onmicrosoft.com +44 (0)7956 031077

About Levicept – www.levicept.com

Levicept Ltd is a UK-based biotechnology company developing the first in a new class of novel, safe and efficacious biological therapies, LEVI-04 [p75NTR-Fc], for the treatment of osteoarthritis and chronic pain. LEVI-04 inhibits NT-3, one of the neurotrophin family of proteins. LEVI-04 has completed a Phase II clinical trial in more than 500 patients with osteoarthritis. It is estimated that the market opportunity for drugs that treat osteoarthritis is worth in excess of $10 billion. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures.

Follow us on LinkedIn – https://www.linkedin.com/company/levicept-ltd

NHS-licensed healthcare platform Evaro partners with period tracking app Clue in UK-first integration




NHS-licensed healthcare platform Evaro partners with period tracking app Clue in UK-first integration

Partnership bridges the gap between period tracking and contraception access as nearly half of UK women face barriers to contraception care

LONDON, Oct. 27, 2025 (GLOBE NEWSWIRE) — Evaro, the NHS-licensed embedded healthcare platform, today announces a first-of-its-kind partnership with Clue, the #1 women-led period and cycle tracker trusted by over 100 million worldwide, to provide seamless access to NHS-funded contraception directly through Clue’s app.

This marks the first time a major cycle-tracking platform has integrated prescription healthcare services in the UK, creating a critical solution as the country grapples with an emergency contraception crisis. 2023 data shows the UK had the highest global search volume for emergency contraception and nearly half of UK women face contraception access barriers, with one in 20 patients having to wait at least four weeks to see a GP. The partnership launches as women’s health takes center stage in the government’s NHS modernisation agenda, with digital medicine transformation identified as a key priority.

The integration brings together Clue’s engaged UK user base with Evaro’s proven healthcare delivery platform, which has already served over 1 million patients. Users can transition directly from tracking their cycle in Clue to ordering contraception through Evaro’s embedded pharmacy infrastructure – accessing free NHS-funded contraception with free delivery nationwide. The collaboration offers a completely free and remote alternative to existing digital NHS services which are limited to specific postcodes. The platform delivers healthcare to your door with banking-style simplicity: transparent dashboards, instant access, a fully remote experience, delivery, digital aftercare access, and re-ordering reminders. Essentially, the convenience women expect from modern digital services.

“Nearly half of UK women can’t access basic contraception and I believe this is a systemic failure that technology can solve,” said Dr. Thuria Wenbar, CEO and co-founder of Evaro. “This partnership with Clue represents what I call the ‘banking moment’ for healthcare. Just as we’d never queue at a bank to transfer £20 today, women shouldn’t wait two months for contraception. By providing this NHS service through our infrastructure in partnership with Clue, we’re transforming how hundreds of thousands of women can access reproductive healthcare in the future. Very much, I hope, with the level of convenience that online banking provides today.”

How it works

The service demonstrates how asynchronous healthcare – where consultations happen online at the patient’s convenience rather than requiring real-time appointments – can solve the UK’s healthcare accessibility challenge:

• Users complete a brief online consultation within the Clue app
• Evaro’s certified clinicians review and approve prescriptions
• Eligible patients in the UK will have access to 40 different NHS-funded oral contraceptive options
• Medications are dispensed from Evaro’s GPhC-registered pharmacy and delivered discreetly next-day

“Our mission at Clue is to help women and people with cycles understand their bodies and take control of their health,” said Rhiannon White, CEO of Clue. “By combining science and technology, we are actively changing the way people learn, access, and talk about menstrual and reproductive health around the world. Our partnership with Evaro is another step on that journey and we are delighted to be rolling out this innovative and convenient solution that will provide women with better access to prescription medication and greater agency over their wellbeing.”

The partnership pioneers embedded healthcare – where consumer brands become healthcare access points by integrating Evaro’s full-stack solution with a single line of code.

The service is available immediately to Clue users in the UK, following Evaro’s successful Lovehoney partnership announced in May 2025.

About Evaro

Evaro is an NHS-licensed UK-based company making access to healthcare faster, more convenient and affordable by providing embeddable prescribing and pharmacy infrastructure for the web. Founded by medical professionals Dr Thuria Wenbar and Dr Oskar Wenbar, Evaro enables any brand to offer prescription medication directly to their customers. The company has served over 1 million patients and is one of the few online pharmacy providers to hold Care Quality Commission, General Pharmaceutical Council, and NHS licenses simultaneously. Evaro’s platform currently supports over 80 conditions and has established partnerships with major consumer brands including Lovehoney. Learn more at https://evaro.com/

About Clue

Clue is the #1 women-led period and cycle tracker, loved by over 100 million women and people with cycles around the world.

Beyond period tracking, Clue helps you turn your cycle into a powerful tool to help navigate your health journey by making sense of your hormones and discovering your unique patterns.

Whether you want to simply understand your cycle, try to conceive,
track your pregnancy, or navigate perimenopause, Clue is your intelligent, science-backed, data-driven health guide.

Join the movement that’s changing the future of female health, one data point at a time. Try Clue free, today.

CONTACT: press@helloclue.com

Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference




Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference

VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 23–27 in Boston, Massachusetts. The Company’s poster, titled “Novel ATR inhibitors with CNS penetrance developed by artificial intelligence,” highlights promising results from its AI-driven kt-5000AI drug discovery program for Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) inhibitors for cancer therapy.

Through its collaboration with Variational AI, Rakovina Therapeutics utilized the Enki™ generative AI platform to identify novel small-molecule candidates predicted to meet a defined target product profile for CNS-penetrant ATR inhibition. Data presented at the conference confirm that multiple lead compounds achieved this profile, demonstrating potent ATR inhibition together with clear evidence of central nervous system exposure.

While multiple ATR inhibitors are in development globally, none have yet demonstrated meaningful central nervous system penetration. Rakovina’s kt-5000AI program is advancing next-generation, AI-designed ATR inhibitors with confirmed CNS exposure, potentially extending the benefits of ATR-targeted therapy to patients with primary brain tumors and brain metastases, where effective treatments remain limited.

In cell-based assays, multiple compounds demonstrated:

• >50% inhibition of ATR activity below 200 nM;
• potency exceeding reference compounds such as ceralasertib, tuvusertib, and elimusertib;
• equal selectivity across the PIKK kinase family compared to reference compounds; and
• metabolic stability following incubation with human liver microsomes

In in vivo pharmacokinetic studies, lead compounds demonstrated:

• measurable drug concentrations in both plasma and brain tissue following intraperitoneal dosing at 5 mg/kg, indicating CNS penetration; and
• good tolerability after single-dose administration, supporting continued optimization and preclinical development

“Presenting at AACR-NCI-EORTC is an opportunity to highlight Rakovina’s progress in translating AI-discovered compounds into preclinical validation to the scientific community,” said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “ATR is a central regulator of DNA damage repair and a validated target across multiple tumor types. Developing ATR inhibitors capable of penetrating the blood–brain-barrier could expand treatment options for patients with primary brain tumors and brain metastases, areas where few effective therapies exist.”

About the AACR-NCI-EORTC¹
Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2025 Molecular Targets and Cancer Therapeutics conference attracts academics, scientists, regulatory agency staff, investors, and biotech and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. For more information, please visit: https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/

About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:
This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

For Further Information Contact:
Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432

¹ AACR (American Association for Cancer Research) https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2025/, accessed October 13, 2025